AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026? The Motley Fool
Covered in this story
What has happened since
- AbbVie is up 14.0% since this was published, 39 days ago.
- Novo Nordisk is down 8.8% since this was published, 39 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on AbbVie
- UBS: $276 → $275 by Oct 2027 · Neutral via GuruFocus
- Bank of America: $262 → $289 by Sep 2027 · Buy via AOL.com
- Wolfe Research: $263 → $300 by Sep 2027 · Outperform via Yahoo Finance
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $ABBV yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on AbbVie →Dalsna Finance is currently tracking 47 stories mentioning AbbVie, the earliest published 29 Apr 2026.
Summary aggregated from The Motley Fool's public RSS feed. The full reporting belongs to The Motley Fool — please read it on their site.